Cabozantinib S-malate for Metastatic Lung Small Cell Carcinoma
This study is evaluating whether a combination of two drugs may help treat cancer in patients with HIV.
See full descriptionAbout the trial for Metastatic Lung Small Cell Carcinoma
Treatment Groups
This trial involves 2 different treatments. Cabozantinib S-malate is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 1 and are in the first stage of evaluation with people.
About The Treatment
Eligibility
This trial is for patients born any sex aged 18 and older. You must have received newly diagnosed for Metastatic Lung Small Cell Carcinoma or one of the other 126 conditions listed above. There are 10 eligibility criteria to participate in this trial as listed below.
Approximate Timelines
Measurement Requirements
This trial is evaluating whether Cabozantinib S-malate will improve 1 primary outcome, 2 secondary outcomes, and 4 other outcomes in patients with Metastatic Lung Small Cell Carcinoma. Measurement will happen over the course of Baseline up to 16 weeks post treatment.
Patient Q & A Section
What is carcinoma, ovarian epithelial?
Carcinoma, ovarian epithelial is a cancer formed in the ovary, and typically spreads to other parts of the body. This cancer is usually discovered early in a woman's life, because of the symptoms.\n
Can carcinoma, ovarian epithelial be cured?
[Even though the incidence of advanced stage, grade III-IV, and bulky carcinoma is higher than of stage-involves, we have not found, until now, differences in long-term prognosis, with no evidence of metastatic, locally recurred metastases or locoregional progression (LRP)(HIT B-4) in our center]. [Moreover, this has not led to change in treatment plan (i.e., surgery or chemotherapy) for our patients with advanced stage carcinoma, grade III-IV, and bulky carcinoma.
What are common treatments for carcinoma, ovarian epithelial?
Women with carcinoma, ovarian epithelial of any stage should receive chemotherapy unless they cannot tolerate this treatment. Most patients are monitored for the potential emergence of secondary tumors while they are being treated.
What are the signs of carcinoma, ovarian epithelial?
The signs of carcinoma, ovarian epithelial, include pelvic pain, adnexa enlargement, dyspareunia, an absent, a hard, or a thick PRA, frequent or painful urination, a palpable pelvic mass, dysuria, fatigue, and abdominal discomfort.
What causes carcinoma, ovarian epithelial?
The vast majority of carcinomas from the ovary are associated with borderline or diffuse, rather than papillary, trophoblast cells. Papillary trophoblast cells may secrete large amounts of proinflammatory factors which could explain the increased proliferation seen in ovarian cancers. This contrasts with adenosarcina, where most lesions are predominantly borderline cells.
How many people get carcinoma, ovarian epithelial a year in the United States?
The data in this report is preliminary given that the overall number of people are not differentiated by gender and by race/ethnicity. The lack of data on the overall annual risk of OC may not reflect a true distribution of OC in a population.
Who should consider clinical trials for carcinoma, ovarian epithelial?
Although some clinical trials on carcinoma or ovarian epithelial are conducted in patients with different cancer types, enrollment of patients with a common type of this cancer is recommended.
Have there been any new discoveries for treating carcinoma, ovarian epithelial?
For most patients with malignant COC or epithelial [ovarian cancer](https://www.withpower.com/clinical-trials/ovarian-cancer), the current therapeutic approach can achieve reasonably good response rates. However, for a small number of these patients, the treatment may not be effective even though the number of cycles might be increased. The overall survival was also lower than expected among women with COC who received chemotherapy. This may be related to the fact that the chemotherapy-induced COC is a chemoresistant cancer, because chemotherapy might alter the biochemistry of the cancer cells.
What are the common side effects of cabozantinib s-malate?
The common adverse events reported in these studies were typical of the indications for cabozantinib, including constipation, fatigue, headache, diarrhea, fatigue, nausea, dizziness, and rash. However, no major difference in tolerability was observed across indications, including those not targeted by cabozantinib, and no indication-specific information was found in the published studies.
What is the primary cause of carcinoma, ovarian epithelial?
The present study provides evidence to indicate that carcinoma, ovarian epithelial is the most common benign primary mass in the ovary. Therefore, when evaluating patients with ovarian neoplasms, medical imaging techniques can play a very important role as they assist in differentiating between benign and malignant tumors.
Does cabozantinib s-malate improve quality of life for those with carcinoma, ovarian epithelial?
In patients with carcinoma, cabozantinib improves QOL in all three domain areas examined, in both healthy and diseased subjects. QOL is not limited to improvements in nausea and pain and can be extended to improvements in overall distress and physical functioning. Combining cabozantinib oncology therapy with other treatments may be a means by which patients with cancer may be able to improve their QOL.
Does carcinoma, ovarian epithelial run in families?
Despite recent studies demonstrating a genetic basis for O-CRL, O-CRLs themselves are often found in families, a finding consistent with a genetic etiology for the disease. It is hypothesized that O-CRLs are due to a low-hanging fruit of genetic predisposition.